Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $21 and keeps a Buy rating on the shares after meeting with its management to discuss the company’s DMD clinical programs, particularly, ENTR-601-44 and ENTR-601-45. The company’s robust cash position and multiple clinical data readouts anticipated in 2026 drive the firm’s optimism, though Roth is also acknowledging the broader negative sentiment enshrouding the company’s stock, partly fueled by a lack of value driving data catalyst events in 2025, the analyst tells investors in a research note.